Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Recruiting Not applicable Interventional

Intensive Case Management Between VA and Community Care for Suicide Prevention

NCT07534358
View directory record Official record
Conditions
Suicidal Ideation, Mental Health Issue, Social Determinants of Health
Interventions
SUicidE PRevention intensive CasE management and coorDination in Community CarE (SUPERCEDE), Present centered therapy
Behavioral
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Saline-Controlled Study of nSTRIDE APS for Knee Osteoarthritis

NCT02905240
View directory record Official record
Conditions
Osteoarthritis
Interventions
nSTRIDE APS, Saline
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years to 80 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Pulse Pressure and Post-epidural Fetal Heart Rate Changes

NCT02565485
View directory record Official record
Conditions
Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery
Interventions
Lactated Ringer's
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 22, 2026, 5:58 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

NCT05229068
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Missoula, Montana • Norfolk, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-induced Parosmia

NCT06253806
View directory record Official record
Conditions
COVID-19-Induced Parosmia
Interventions
Stellate Ganglion Block, Placebo Sham Injection
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

NCT00656578
View directory record Official record
Conditions
Pain
Interventions
4975, Placebo
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Bakersfield, California • Owings Mills, Maryland • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

NCT05223478
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
3 Years to 11 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Longwood, Florida • Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Lu AF82422 in Participants With Multiple System Atrophy

NCT05104476
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Fountain Valley, California • La Jolla, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)

NCT04163458
View directory record Official record
Conditions
Infertility
Interventions
MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen), Placebo (for MENOPUR powder and solvent for solution for injection)
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Tempe, Arizona • San Diego, California • Farmington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Role of Topical Tranexamic Acid in Total Hip Arthroplasty

NCT01866943
View directory record Official record
Conditions
Post Operative Blood Loss
Interventions
Tranexamic Acid, Normal Saline Solution
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety Study of DFN-15

NCT03006276
View directory record Official record
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional

Palliative Care Study in Patients With Advanced Cancer

NCT00127517
View directory record Official record
Conditions
Cancer
Interventions
peptide-nucleic acid solution AVR118
Drug
Lead sponsor
Advanced Viral Research Corp
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Vincennes, Indiana • Fresh Meadows, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 2 Interventional

Peripheral Modulation of Muscle Stiffness and Spasticity

NCT03306615
View directory record Official record
Conditions
Muscle Spasticity
Interventions
Hyaluronidase, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Perio. Maint. With Diode LBR

NCT05276817
View directory record Official record
Conditions
Chronic Periodontitis
Interventions
Epic Diode, HP, Sham
Device · Drug
Lead sponsor
Biolase Inc
Industry
Eligibility
30 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

NCT04350138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2,606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

CBD for Pain Following Orthopedic Shoulder Surgery

NCT06381791
View directory record Official record
Conditions
Shoulder Osteoarthritis, Rotator Cuff Injuries
Interventions
Epidiolex, Placebo oral solution
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Slit Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel for Rejuvenation of the Cheek

NCT02679924
View directory record Official record
Conditions
Problem of Aging
Interventions
Hyaluronic Acid filler, Sham Comparator
Device · Other
Lead sponsor
Isabella Guiha
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

NCT01356160
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 22, 2026, 5:58 AM EDT